Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.04 USD

29.04
4,151,466

-0.05 (-0.17%)

Updated Sep 30, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA

by Zacks Equity Research

FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to AZN's Imfinzi for New Cancer & Other Updates

by Kinjel Shah

FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.

Pfizer (PFE) Streptococcus Jab Gets FDA's Breakthrough Tag

by Zacks Equity Research

Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.

Zacks Market Edge Highlights: General Electric, IBM, Pfizer, Bank of America and McDonald's

by Zacks Equity Research

Zacks Market Edge Highlights: General Electric, IBM, Pfizer, Bank of America and McDonald's

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Pfizer (PFE) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $46.13, moving +0.81% from the previous trading session.

Tracey Ryniec headshot

Should Stock Investors Buy and Hold Forever?

by Tracey Ryniec

The pros and cons of buying a bunch of blue-chip stocks and holding them for 20+ years.

Spero (SPRO) Up Following Positive FDA Update for UTI Drug

by Zacks Equity Research

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland

by Zacks Equity Research

Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.

Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?

by Zacks Equity Research

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation

by Zacks Equity Research

The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.

Novo Nordisk (NVO) to Tap Into SCD Space With Forma Acquisition

by Zacks Equity Research

Novo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space.

Ekta Bagri headshot

PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion

by Ekta Bagri

Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.

The Zacks Analyst Blog Highlights Pfizer /BioNTec and Moderna's

by Zacks Equity Research

Pfizer /BioNTec and Moderna are part of The Zacks top Analyst Blog.

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DHS

Kinjel Shah headshot

FDA Authorizes Pfizer, Moderna's Omicron-Based Boosters

by Kinjel Shah

Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) develop the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA's recommendation.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Authorization of Omicron Boosters, SNY's Xenpozyme & More

by Kinjel Shah

FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.

Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News

by Zacks Equity Research

Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.

Aerie (AERI) Rallies 205.6% in the Past Three Months: Here's Why

by Zacks Equity Research

Aerie (AERI) shares have skyrocketed in the past three months after the company announced its definitive agreement with Alcon, wherein the latter will acquire the former for $770 million.

Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DHS

Moderna's (MRNA) Omicron Based Jab gets Approval in Australia

by Zacks Equity Research

Moderna (MRNA) receives provisional approval in Australia for its Omicron-containing bivalent booster vaccine mRNA-1273.214 in adults, making it the first bivalent COVID-19 vaccine approved for use in Australia.

Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based Booster

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) complete submission of conditional marketing authorization to the European Medicines Agency for Omicron BA.4/BA.5-adapted bivalent vaccine.

Moderna (MRNA) Sues Pfizer and BioNTech Over COVID Jab

by Zacks Equity Research

Moderna (MRNA) sues Pfizer and BioNTech, alleging that Comirnaty infringes on patents that Moderna filed from 2010 to 2016 related to its mRNA technology.

The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer

by Zacks Equity Research

Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.